- Home
- HIMS vs AXSM Comparison
HIMS vs AXSM Comparison
Compare HIMS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMS
- AXSM
- Stock Information
- Founded
- HIMS 2017
- AXSM 2012
- Country
- HIMS United States
- AXSM United States
- Employees
- HIMS N/A
- AXSM N/A
- Industry
- HIMS Medical/Nursing Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- HIMS Health Care
- AXSM Health Care
- Exchange
- HIMS Nasdaq
- AXSM Nasdaq
- Market Cap
- HIMS 6.0B
- AXSM 5.1B
- IPO Year
- HIMS N/A
- AXSM 2015
- Fundamental
- Price
- HIMS $52.77
- AXSM $110.66
- Analyst Decision
- HIMS Hold
- AXSM Strong Buy
- Analyst Count
- HIMS 12
- AXSM 16
- Target Price
- HIMS $38.00
- AXSM $171.13
- AVG Volume (30 Days)
- HIMS 48.5M
- AXSM 607.7K
- Earning Date
- HIMS 08-04-2025
- AXSM 05-05-2025
- Dividend Yield
- HIMS N/A
- AXSM N/A
- EPS Growth
- HIMS N/A
- AXSM N/A
- EPS
- HIMS 0.68
- AXSM N/A
- Revenue
- HIMS $1,784,353,000.00
- AXSM $432,157,000.00
- Revenue This Year
- HIMS $62.48
- AXSM $63.16
- Revenue Next Year
- HIMS $20.34
- AXSM $60.81
- P/E Ratio
- HIMS $77.40
- AXSM N/A
- Revenue Growth
- HIMS 85.99
- AXSM 72.16
- 52 Week Low
- HIMS $13.47
- AXSM $64.11
- 52 Week High
- HIMS $72.98
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- HIMS 52.99
- AXSM 56.53
- Support Level
- HIMS $52.09
- AXSM $101.41
- Resistance Level
- HIMS $67.37
- AXSM $111.41
- Average True Range (ATR)
- HIMS 4.80
- AXSM 2.88
- MACD
- HIMS -1.35
- AXSM 0.60
- Stochastic Oscillator
- HIMS 9.68
- AXSM 91.68
About HIMS Hims & Hers Health Inc.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.